Cargando…
Inhibiting MAPK14 showed anti-prolactinoma effect
BACKGROUND: The specific underlying pathogenesis of prolactinoma has not been clarified yet, to the best of our knowledge. p38 mitogen-activated protein kinase (MAPK) signaling including p38α MAPK (MAPK14), p38β (MAPK11), p38γ (MAPK12) and p38δ (MAPK13) is associated with the development and progres...
Autores principales: | Ding, Qiao-yan, Zhang, Yu, Ma, Li, Chen, Yong-gang, Wu, Jin-hu, Zhang, Hong-feng, Wang, Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487756/ https://www.ncbi.nlm.nih.gov/pubmed/32894113 http://dx.doi.org/10.1186/s12902-020-00619-z |
Ejemplares similares
-
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Wang, Shuman, et al.
Publicado: (2021) -
Antiprolactinoma Effect of Hordenine by Inhibiting MAPK Signaling Pathway Activation in Rats
por: Wang, Xiong, et al.
Publicado: (2020) -
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
por: Zhu, Kejing, et al.
Publicado: (2022) -
Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old
por: Zhao, Yi, et al.
Publicado: (2019) -
Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells
por: Huang, Jinxiang, et al.
Publicado: (2017)